Abstract
Objective:To compare preterm birth rate and neonatal outcome in twin gestations randomized to either 17 alpha-hydroxyprogesterone caproate (17P) or placebo.Materials and Methods:Women with twin gestations between 20–30 weeks were randomized to receive weekly injections of either 250mg 17P injection (Group I), or placebo (Group II). Maternal and neonatal outcome data was recorded.Results:Thirty twin intrauterine pregnancies were randomized; 16 received 17P and 14 received placebo. Demographic data as well as past history and gestational age at randomization were equivalent between groups (P = 0.286–0.847). All patients in both groups were Medicaid recipients. The incidence of preterm labor (P = 0.980), and premature rupture of the membranes (P = 0.525) were the same between groups. Gestational age at delivery was also similar between 17P (33.9 weeks) versus placebo (33.1 weeks, P = 0.190) as was the incidence of preterm birth <35 weeks (44% vs 79%, P = 0.117). Infant weight (P = 0.641), Apgar score at 5 minutes (P = 0.338) as well as neonatal morbidity such as respiratory distress syndrome (P = 0.838), patent ductus arteriosus (P = 0.704), intraventricular hemorrhage (P = 0.851) and necrotizing enterocolitis (P = 0.946) showed no difference. Days spent in the NICU among 17P (18.4) versus placebo (17.3, P = 0.155), neonatal death (P = 0.359) and those infants discharged with neurologic handicap (P = 0.594) were not different between groups.Conclusion:Amongst this group of twin gestations weekly 17HP injections did not reduce the incidence of preterm birth or the complications associated with prematurity.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1.Martin JA, Hamilton BE, Sutton PD, et al. Births: Final Data for 2004. National Vital Statistics Reports. Hyattsville, MD, National Center for Health Statistics, 2006, vol 55, no. 1.2.Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149–154.KeirseMJProgestogen administration in pregnancy may prevent preterm delivery.Br J Obstet Gynaecol199097149-1543.Meis PJ, Klebanoff M, Thom E, et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–2385.MeisPJ]]KlebanoffM]]ThomE&etal;National Institute of Child Health and Human Development Maternal-Fetal Medicine Units NetworkPrevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.N Engl J Med20033482379-23854.da Fonseca EB, Bittar RE, Carvalho MH, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–424.da FonsecaEB]]BittarRE]]CarvalhoMH&etal;Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study.Am J Obstet Gynecol2003188419-4245.Sanchez-Ramos L, Kaunitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273–279.Sanchez-RamosL]]KaunitzAM]]DelkeIProgestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.Obstet Gynecol2005105273-2796.Joseph KS, Allen AC, Dodds L, et al. Causes and consequences of recent increases in preterm birth among twins. Obstet Gynecol 2001;98:57–64.JosephKS]]AllenAC]]DoddsL&etal;Causes and consequences of recent increases in preterm birth among twins.Obstet Gynecol20019857-647.Kiely JL. What is the population-based risk of preterm birth among twins and other multiples? Clin Obstet Gynecol 1998;41:3–11.KielyJLWhat is the population-based risk of preterm birth among twins and other multiples?Clin Obstet Gynecol1998413-118.Pieber D, Allport VC, Hills F, et al. Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol Hum Reprod 2001;7:875–879.PieberD]]AllportVC]]HillsF&etal;Interactions between progesterone receptor isoforms in myometrial cells in human labour.Mol Hum Reprod20017875-8799.Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980;56:692–695.Hartikainen-SorriAL]]KauppilaA]]TuimalaRInefficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy.Obstet Gynecol198056692-69510.Rouse DJ, Caritis SN, Peaceman AM, et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 2007;357:454–461.RouseDJ]]CaritisSN]]PeacemanAM&etal;National Institute of Child Health and Human Development Maternal-Fetal Medicine Units NetworkA trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.N Engl J Med2007357454-46111.Northen AT, Norman GS, Anderson K, et al; National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007;110:865–872.NorthenAT]]NormanGS]]AndersonK&etal;National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) NetworkFollow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo.Obstet Gynecol2007110865-87212.Burkett G, Bauer CE, Morrison JC, et al. Effect of prenatal dexamethasone administration on prevention of respiratory distress syndrome in twin pregnancies. J Perinatol 1986;6:304–308.BurkettG]]BauerCE]]MorrisonJC&etal;Effect of prenatal dexamethasone administration on prevention of respiratory distress syndrome in twin pregnancies.J Perinatol19866304-30813.Romero R. Prevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment. Ultrasound Obstet Gynecol 2007;30:675–686.RomeroRPrevention of spontaneous preterm birth: the role of sonographic cervical length in identifying patients who may benefit from progesterone treatment.Ultrasound Obstet Gynecol200730675-68614.DeFranco EA, O’Brien JM, Adair CD, et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:697–705.DeFrancoEA]]O’BrienJM]]AdairCD&etal;Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: a secondary analysis from a randomized, double-blind, placebo-controlled trial.Ultrasound Obstet Gynecol200730697-70515.Thornton JG. Progesterone and preterm labor-still no definite answers. N Engl J Med 2007;357:499–501.ThorntonJGProgesterone and preterm labor-still no definite answers.N Engl J Med2007357499-501
